Vertex Pharmaceuticals Incorporated (LON: 0QZU)
London
· Delayed Price · Currency is GBP · Price in USD401.39
+10.75 (2.75%)
Dec 23, 2024, 7:12 PM BST
Vertex Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 29, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 30, 2022 | Dec '21 Dec 30, 2021 | Dec '20 Dec 30, 2020 | Dec '19 Dec 30, 2019 | 2018 - 2014 |
| Net Income | -479.8 | 3,620 | 3,322 | 2,342 | 2,712 | 1,177 | Upgrade
|
| Depreciation & Amortization | 207.9 | 169.5 | 148.3 | 125.6 | 109.5 | 106.9 | Upgrade
|
| Other Amortization | 11.8 | 11.8 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 50.9 | 0.6 | 149.1 | -17.1 | -311.9 | -197.6 | Upgrade
|
| Stock-Based Compensation | 739.3 | 581.2 | 491.3 | 441.4 | 429.5 | 360.5 | Upgrade
|
| Other Operating Activities | -579.2 | -579.7 | -321.6 | -143.3 | 369.1 | 188.8 | Upgrade
|
| Change in Accounts Receivable | -152.9 | -84.1 | -358.6 | -274.7 | -223.4 | -225.6 | Upgrade
|
| Change in Inventory | -439.8 | -322.9 | -136.4 | -92.8 | -132 | -64 | Upgrade
|
| Change in Accounts Payable | 9.3 | 48.7 | 120.8 | 31.9 | 51.3 | -22.8 | Upgrade
|
| Change in Other Net Operating Assets | -210.1 | 92.6 | 715 | 230.4 | 249.7 | 246.3 | Upgrade
|
| Operating Cash Flow | -842.6 | 3,537 | 4,130 | 2,644 | 3,254 | 1,569 | Upgrade
|
| Operating Cash Flow Growth | - | -14.35% | 56.23% | -18.75% | 107.32% | 23.54% | Upgrade
|
| Capital Expenditures | -263.2 | -200.4 | -204.7 | -235 | -259.8 | -75.4 | Upgrade
|
| Cash Acquisitions | - | - | -295.9 | - | - | -1,154 | Upgrade
|
| Sale (Purchase) of Intangibles | -245.7 | -58 | - | - | - | - | Upgrade
|
| Investment in Securities | -3,334 | -2,883 | 179.5 | -105.9 | 359.2 | -5.7 | Upgrade
|
| Other Investing Activities | 7.9 | - | - | - | - | - | Upgrade
|
| Investing Cash Flow | -3,835 | -3,142 | -321.1 | -340.9 | 99.4 | -1,235 | Upgrade
|
| Long-Term Debt Issued | - | 1.8 | 3.5 | 28.3 | 13.3 | 10 | Upgrade
|
| Total Debt Issued | 1.8 | 1.8 | 3.5 | 28.3 | 13.3 | 10 | Upgrade
|
| Long-Term Debt Repaid | - | -44.9 | -85.5 | -47 | -42.3 | -39.2 | Upgrade
|
| Total Debt Repaid | -44.3 | -44.9 | -85.5 | -47 | -42.3 | -39.2 | Upgrade
|
| Net Debt Issued (Repaid) | -42.5 | -43.1 | -82 | -18.7 | -29 | -29.2 | Upgrade
|
| Issuance of Common Stock | 126.7 | 134.6 | 186.3 | 102 | 264.9 | 343.2 | Upgrade
|
| Repurchase of Common Stock | -1,310 | -653.7 | -172 | -1,561 | -739.4 | -192 | Upgrade
|
| Other Financing Activities | 2 | - | - | - | -1.8 | 4.8 | Upgrade
|
| Financing Cash Flow | -1,223 | -562.2 | -67.7 | -1,478 | -505.3 | 126.8 | Upgrade
|
| Foreign Exchange Rate Adjustments | 32.1 | 26.9 | -29.2 | -13.4 | 20.6 | 1.6 | Upgrade
|
| Net Cash Flow | -5,869 | -139.7 | 3,712 | 811.2 | 2,868 | 462.4 | Upgrade
|
| Free Cash Flow | -1,106 | 3,337 | 3,925 | 2,409 | 2,994 | 1,494 | Upgrade
|
| Free Cash Flow Growth | - | -14.99% | 62.97% | -19.55% | 100.39% | 27.16% | Upgrade
|
| Free Cash Flow Margin | -10.41% | 33.81% | 43.95% | 31.80% | 48.24% | 35.89% | Upgrade
|
| Free Cash Flow Per Share | -4.29 | 12.81 | 15.15 | 9.27 | 11.37 | 5.73 | Upgrade
|
| Cash Interest Paid | 38.3 | 43.1 | 52.3 | 56.3 | 54.5 | 55.6 | Upgrade
|
| Cash Income Tax Paid | 1,569 | 1,677 | 1,058 | 476.3 | 191.8 | 24.7 | Upgrade
|
| Levered Free Cash Flow | 3,063 | 3,510 | 3,307 | 2,402 | 2,232 | 936.53 | Upgrade
|
| Unlevered Free Cash Flow | 3,087 | 3,538 | 3,342 | 2,441 | 2,268 | 973.09 | Upgrade
|
| Change in Net Working Capital | 209.5 | -341.4 | -170.3 | 324 | -80.11 | 170.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.